literature

HIV mutation literature information.

Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.

PMID: 16925730 2006 HIV medicine

Abstract: Resistance to EFV (K103N and others) or 3TC (M184V) developed most frequently (8.3% and 5.8%, respectively) and similarly in the two arms.

HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.

PMID: 16945074 2006 HIV medicine

Abstract: The M184V and Q151M mutations were the most commonly co-selected substitutions.

HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon.

PMID: 16964825 2006 Antiviral therapy

Abstract: In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]).

Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation.

PMID: 16970827 2006 AIDS research and therapy

Result: An HLA-A2-restricted RT epitope including the lamivudine-associated M184V mutation has been characterized.

Result: In another study, epitopes incorporating M41L, L74V, M184V and T215Y in RT were demonstrated by ELISPOT.

In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

PMID: 16982781 2006 Antimicrobial agents and chemotherapy

Abstract: Abacavir resistance was characterized by the accumulation of the M184V, Y115F, and K65R mutations in the abacavir culture, while the M184V and L74V mutations were selected in combination with lamivudine.

Abstract: At intermediate concentrations of emtricitabine and tenofovir, viruses harboring the K65R mutation or a novel K65N and K70R double mutation grew before they gave rise to mutants with K65R and M184V/I double mutations at higher emtricitabine concentrations.

Abstract: Emtricitabine- and lamivudine-resistant HIV-1 isolates with the M184I or M184V

Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.

PMID: 17009933 2006 Expert review of anti-infective therapy

Abstract: FTC selects for M184V mutation less frequently than lamivudine.

Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action.

PMID: 17020946 2006 Journal of virology

Abstract: While INDOPY-1 susceptibility is unaffected by mutations associated with NNRTI or multidrug NRTI resistance, mutations M184V and Y115F are associated with decreased susceptibility, and mutation K65R confers hypersusceptibility to INDOPY-1.

Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide.

PMID: 17042328 2006 Antiviral chemistry & chemotherapy

Abstract: Several new compounds were highly active in lymphocytes infected with primary isolates carrying the K103N-V1081-M184V and L1001-V1081 mutations.

Frequency of protease and reverse transcriptase drug resistance mutations in naive HIV-infected patients.

PMID: 17045121 2006 Archives of medical research

Abstract: RESULTS: One of 36 isolates (2.8%) had the M184V resistance mutation to nucleoside retrotranscriptase inhibitors.

Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

PMID: 17057610 2006 Journal of acquired immune deficiency syndromes (1999)

Abstract: Six viral failures occurred, including 2 with K65R mutations (alone or associated with Y115F and M184V).

Browser Board

Co-occurred Entities

Filtrator